Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2000

View Archived Issues

Prana to adapt Alzheimer's therapy for use in Creutzfeldt-Jakob disease

Tripedia receives FDA approval for use in the entire DTP immunization series

Licensing opportunity from NIH: cloned hepatitis C virus genome

Licensing opportunity from NIH: HCV and bovine viral diarrhea virus chimeric genomes

Corixa overviews key developments

SignalGene to acquire Nova Molecular

Phase I PentaLyte clinical trial successfully completed

ERS congress presentations describe efficacy and safety of roflumilast

Recent clinical results support use of alpha1-blockers in secondary pulmonary hypertension

Selective ETA receptor antagonist LBL-031 inhibits ET-1- and LPS-induced microvascular leakage

Schering-Plough presents newly discovered selective M2 antagonists at ACS

Factor Xa inhibitors with anticoagulant and antithrombotic effects identified at Lilly

Bicyclic heteroarylethanolamine-containing compounds as potent and selective beta3-AR agonists

Cytogen and Advanced Magnetics terminate merger, enter marketing agreement

ACS news: 3-D presents recently designed iodinated thrombin inhibitors

Novel N-hydroxyformamide inhibitor of TACE and TNF production: GW-4459

Topiramate has beneficial effects in transformed migraine

New formulation of Pfizer's Zeldox approved in Sweden; launch imminent

New use for topiramate: bulimia nervosa Rx

Anticonvulsants for cluster headache

U. of Michigan team discovers non-nucleoside antivirals

Peptide immunomodulating compounds reported in patent by Cytran

Potential therapeutic agents for pain identified by AstraZeneca

Bayer investigates inhibition of raf kinase signaling pathway as new approach to cancer

Substituted imidazoles as H3 receptor antagonists emerge from joint research program

Bayer claims nonsteroidal progesterone receptor modulators and their use

Schering-Plough seeks FDA approval of desloratadine for chronic idiopathic urticaria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...